What is Personalized Medicine?
Definition
Personalized medicine (also called precision medicine) is a medical model that uses an individual's genetic, environmental, and lifestyle information to guide clinical decisions. Rather than prescribing the same drug at the same dose to every patient with a given condition, personalized medicine selects therapies and dosages based on the patient's unique biological profile — particularly their genomic data.
Detailed Explanation
The concept of personalized medicine became mainstream with the completion of the Human Genome Project in 2003, but the field's roots trace to blood typing in the early 1900s and the discovery that genetic variation in drug-metabolizing enzymes causes adverse reactions in the 1950s. Today, personalized medicine encompasses several overlapping disciplines: pharmacogenomics (matching drugs to genotype), targeted cancer therapy (selecting treatments based on tumor genomics), gene therapy (replacing defective genes), and computational drug design (creating molecules optimized for individual genetic profiles). The National Institutes of Health's All of Us Research Program, launched in 2018, aims to collect genomic and health data from 1 million Americans to accelerate personalized medicine research.
In practice, personalized medicine translates genomic information into clinical action through decision-support tools. A patient undergoes genetic testing (via targeted panels, whole-exome, or whole-genome sequencing), the results are interpreted against clinical databases like ClinVar and PharmGKB, and pharmacogenomic guidelines from CPIC or DPWG provide genotype-specific dosing recommendations. For example, a patient identified as a CYP2C19 poor metabolizer before starting clopidogrel would be switched to an alternative antiplatelet drug. Similarly, patients with HLA-B*57:01 are screened before prescribing abacavir to prevent potentially fatal hypersensitivity reactions. These interventions have demonstrated both clinical benefit and cost-effectiveness.
PepFold extends personalized medicine into the domain of therapeutic peptide design. Traditional peptide drug development produces a single peptide intended for all patients. PepFold's pharmacogenomic pipeline generates peptide candidates tailored to a specific patient's genetic variants. By accounting for how SNPs alter target protein structure, receptor binding, and drug metabolism, the system produces candidates optimized for the individual's molecular biology. This represents a new paradigm: personalized peptide therapeutics designed computationally from genomic data.
Related Terms
Pharmacogenomics (PGx) is the study of how an individual's genetic makeup influences their response to medications. It combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, personalized drug therapies based on a patient's DNA.
What is a SNP (Single Nucleotide Polymorphism)?A single nucleotide polymorphism (SNP, pronounced 'snip') is a variation at a single position in a DNA sequence among individuals. SNPs are the most common type of genetic variation in humans, with approximately 4-5 million SNPs per individual genome and over 660 million cataloged in the dbSNP database.
What are CYP450 Enzymes?Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that catalyze the oxidative metabolism of the majority of clinically used drugs. In humans, 57 CYP genes encode enzymes that metabolize endogenous substrates (steroids, bile acids, fatty acids) and xenobiotics (drugs, environmental chemicals, dietary compounds). Five CYP enzymes — CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 — are responsible for metabolizing approximately 90% of all drugs in clinical use.
What is a Poor Metabolizer?A poor metabolizer (PM) is an individual who carries genetic variants resulting in little or no functional activity of a drug-metabolizing enzyme, most commonly a cytochrome P450 (CYP450) enzyme. Poor metabolizers process certain drugs much more slowly than normal metabolizers, which can lead to drug accumulation, increased plasma levels, prolonged drug effects, and a higher risk of adverse drug reactions at standard doses.
What is ClinVar?ClinVar is a freely accessible public database maintained by the National Center for Biotechnology Information (NCBI) that aggregates information about the relationships between human genetic variants and observed health conditions (phenotypes). Submitters — including clinical laboratories, research groups, and expert panels — classify variants using a standardized five-tier system: pathogenic, likely pathogenic, uncertain significance (VUS), likely benign, and benign.
Related SNPs
Apply This Knowledge with PepFold
Submit rsIDs and get ranked peptide candidates with 3D structures and Fmoc-SPPS synthesis protocols in under 2 minutes.